Selby G B, Saez R A, Epstein R B, Slease R B, Confer D L
University of Oklahoma Health Sciences Center.
J Okla State Med Assoc. 1993 Dec;86(12):599-603.
Allogeneic bone marrow transplantation (BMT) is potentially curative therapy for leukemia, lymphoma, and marrow failure. Ninety-two patients have received allogeneic BMT at Oklahoma Memorial Hospital in the past 10 years. Patients with acute myelogenous leukemia (AML; N = 30), chronic myelogenous leukemia (CML; N = 27), acute lymphoblastic leukemia (ALL; N = 12), myelodysplastic syndromes (MDS; N = 8), lymphomas (N = 8), and aplastic anemia (N = 7) were treated with a variety of myeloablative preparative regimens. The major causes of mortality were bacterial, viral, and fungal infections, or disease relapse. Standard and high risk (refractory or multiply-relapsed disease) AML, CML, and ALL patients had median survivals of 14.5 months vs. 3 months, > 18 months vs. 9 months, and 10 months vs. 4.5 months (p = 0.01), respectively. At 7.5 years median follow-up, 71% of the aplastic anemia patients are disease-free. Guidelines for the optimal time for BMT have been developed that encourage transplantation earlier in the course of the disease, thus facilitating better outcomes with these otherwise fatal disorders.
异基因骨髓移植（BMT）是治疗白血病、淋巴瘤和骨髓衰竭的一种潜在的根治性疗法。在过去10年中，有92名患者在俄克拉荷马纪念医院接受了异基因BMT。患有急性髓细胞白血病（AML；n = 30）、慢性髓细胞白血病（CML；n = 27）、急性淋巴细胞白血病（ALL；n = 12）、骨髓增生异常综合征（MDS；n = 8）、淋巴瘤（n = 8）和再生障碍性贫血（n = 7）的患者接受了多种清髓性预处理方案的治疗。死亡的主要原因是细菌、病毒和真菌感染或疾病复发。标准风险和高风险（难治性或多次复发疾病）的AML、CML和ALL患者的中位生存期分别为14.5个月对3个月、> 18个月对9个月、10个月对4.5个月（p = 0.01）。在中位随访7.5年时，71%的再生障碍性贫血患者无病生存。已经制定了BMT最佳时机的指南，鼓励在疾病过程中尽早进行移植，从而使这些原本致命的疾病获得更好的治疗效果。
